SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis


enzyme). The prodrug APX001 (APX) is in clinical development and its efficacy was evaluated in an immunocompromised murine model of disseminated C. auris. Methods. MICs were determined by CLSI M27-A3 method. Mice were immunocompromised for the study. Treatment was initiated 2 hours post challenge. IP treatment groups included a vehicle control, APX 78mg/kg (mpk) BID, 78mpk TID, and 104mpk BID, and anidulafungin (AFG) 10mpk BID. Survival was monitored for 16d post inoculation. Results. Susceptibility. APXA had significantly lower MIC50 and MIC90 values (concentration that inhibits 50 and 90% of the tested isolates, respectively) than the other tested antifungals with a MIC90 of 0.031 μg/mL (Table 1). Survival. 100% mortality in the vehicle-treated control group occurred by 6d. Significant efficacy was observed in all APX treatment groups with 90, 100, and 80% survival observed respectively for APX 78 mpk BID; 78 mpk TID and 104 mpk BID. AFG treatment resulted in 50% survival at 16d. Mice in all of the APX treated groups had a significantly higher % survival compared with the AFG and vehicle groups. Conclusion. APXA was the most active antifungal agent in vitro. The prodrug APX resulted in significantly better survival than AFG in a C. auris disseminated infection model. Thus APX may be a viable treatment for C. auris infections.

Cite this paper

@inproceedings{BorrotoEsoda2017SCY078DS, title={SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis}, author={Katyna Borroto-Esoda and Stephen Barat and David Angulo and Kirsty A Holden and Peter A. Warn}, year={2017} }